

Prostate Cancer Program

Medical Director, Dr. Massimiliano Spaliviero, MD

Cancer Program Nurse, Shannen Harbourne, RN, MSN, OCN

PSA Pre-screening Information

The National Comprehensive Cancer Network (NCCN) has issued new guidelines for <u>prostate cancer screenings</u>. The guidelines were developed from a systematic literature review to ensure that men most likely to benefit from early detection are screened, and to encourage shared decision-making between the patient and physician:

Men who are considering PSA screening should now speak with their physician about the benefits and harms of testing to determine the best course of action.

Screening is for healthy men without a personal history of prostate cancer. Men with known prostate cancer should follow up with their diagnosing physician or seek consultation from a urologist.

Prostate cancer screening is not recommended for men <45 years of age, or those > 75 years old or with less than 10-15 years life expectancy. Men who are at higher risk of prostate cancer (race, family history, etc.) may be eligible to screen earlier starting at age 40.

To reduce the harms of screening, a routine screening interval of two years or more may be preferred over annual screening in those men who have participated in shared decision-making and decided on screening.

Prostate cancer is the most common malignancy and the second most common cause of cancer death in American men. The Prostate Specific Antigen (PSA) blood test and the digital rectal examination (prostate exam or DRE) may help identify prostate cancer in an early stage. This concept; however, has not been scientifically proven and is currently the subject of great debate. All men should be aware of the risks and benefits of screening including, but not limited to the following:

<u>Possible Benefits:</u> Finding prostate cancers that may be at high risk of spreading, so that they can be treated before they spread. In some men this may lower the chance of death from prostate cancer.

<u>Possible Risks:</u> The potential risks of the PSA test are largely related to the choices made based on the test results, such as the decision to undergo further testing and treatment for prostate cancer. These risks include:

False positive test results: This occurs when a man has an abnormal PSA test but does not have prostate cancer. False positive test results can lead to "unnecessary" tests, like a biopsy of the prostate.

Biopsy complication: A biopsy is a procedure that carries its own risks, including pain, bleeding and infection.

Psychological effects: False-positive test results can cause anxiety or distress. If you are diagnosed with prostate cancer, but it appears to be a slow-growing tumor that doesn't result in illness, you may experience significant anxiety knowing it's there which can impact your treatment decisions.

The best evidence supports the use of serum PSA for the early detection of prostate cancer. The value of a DRE as a standalone test is limited, and the prediction ability of a DRE in men with a normal PSA is poor. There is some evidence to support that a combination of PSA and DRE is more effective for the early detection of prostate cancer than either test alone. A DRE should be performed in all men with an abnormal PSA to aid in decisions regarding biopsy.

As a result, you are given the option of having a DRE during your screening.

If you have an abnormal PSA, a DRE is strongly recommended and should be performed by your physician during office follow up, or will be performed during a consultation visit with a urologist for an abnormal PSA

Important Influencing Factors:

The change in the PSA level from one test to the other is suggestive of risk and aggressiveness.

PSA Levels increase with age. Enlarged prostates can have higher PSA levels.

Factors that can affect the PSA level:

Prostatitis
BPH -Benign Prostatic Hypertrophy
Prostate Cancer
PSA level can be influenced by
Ejaculation 48 hours prior to testing,
Certain Medications
Rigorous Exercise

Prostate Cancer Treatment:

All risks and benefits of treatment must be discussed, including active surveillance. (having no surgical or pharmacologic treatment, unless the disease becomes more aggressive.)

Urinary frequency, weak stream, do I have BPH???

Benign Prostatic Hyperplasia (BPH) is a common condition in men over 50 years of age, but may also develop in younger men. In most men, the prostate begins to enlarge in the fourth or fifth decade of life and continues to enlarge with advancing age. The cause of this enlargement has not been identified, and it *does not increase or decrease your risk of prostate cancer*. BPH is usually not a serious threat to your health, but it can seriously affect the quality of your life.

BPH often causes urinary frequency during the day and/or night and may cause sudden urges to urinate or urine leakage. Some men may notice a weak urinary stream and can have difficulty starting urination or difficulty in postponing urination when the urge occurs. There may be a sensation that the bladder is not emptying completely. These urinary symptoms often interfere with a good night's sleep. As a result, you may find yourself modifying your activities to be close to a bathroom. The symptoms can vary in intensity from day to day and progress at different rates in different men. To complicate matters further, the intensity is not always in proportion to the degree of enlargement. In addition, the symptoms of BPH overlap with those of other urinary problems.

Treatment must be individualized based on the cause, pattern and intensity of your type of problem. Treatment of symptomatic BPH ranges from medication in mild cases to various types of surgery for more severe cases. The medications used to treat BPH are usually taken once daily and are safe when prescribed properly and well tolerated by most men. There are several surgical techniques available to treat BPH in those men who do not respond to medication. Some of these can be performed on an outpatient or short stay basis and have low rates of complication and short recovery periods. Please talk to your doctor or urologist about these options and get their advice. If you have questions or need more information about this subject, an appointment can be made to see one of the Stony Brook urologists if desired. Please call Stony Brook Urology at **631-216-9181**

For Screening Information: 631-216-9181



Patient Signature

Prostate Cancer Screening Consent

	Date
Print Name	Screening Location
and sign this form and complete th	ancer Program. In order to be screened, please read the consent entirely ne attached questionnaire. The screening will consist of a prostate specific otional digital rectal exam (DRE). Please arrive no earlier than fifteen e. Thank you.
You may eat normally. Be sure to come rigorous exercise, including bicycle ridir venipuncture to minimize bruising and experience minor discomfort and/or occ the first 24hrs, in 15 minute intervals and	rawing a venous blood specimen of approximately 10 ml. (about 2 teaspoons) from you. well hydrated as it enhances the veins for blood drawing. Please avoid ejaculation and ng, 48 hours prior to testing; please be sure to apply pressure to the site right after the blood loss. Remove the bandage from the site after bleeding has stopped. You may assionally, a bruise or infection may result You may apply a cold pack or ice to site for ad warm packs thereafter. Please remove the tape/band aid from the site as soon as the seening program will not be responsible for expenses related to any further testing or
The DRE may occasionally cause some finds any abnormality, we recommend	ting a gloved index finger into the rectum and gently pressing against the prostate gland. discomfort and a desire to urinate which will not last long. If your examining physician you contact your personal physician or urologist for further testing. This screening enses related to any further testing or treatment if you should require it.
men with above average risk age 4 detection and risk assessment on a	cer Network (NCCN) recommends that all men 45 years and older, (or 0-44) be offered a baseline PSA test and Digital Rectal exam for early n individual basis. The NCCN strongly urges that all men who have taken is with their physician regardless of the result, to discuss the benefits of
consult. Please note that although son	nal, we recommend you contact your personal physician or a urologist for me tumors may be detected by this exam, no test is completely accurate in the more an abnormal exam or PSA result does not necessarily imply the presence
You will receive a mailed letter wit	th your DRE and PSA results within a few weeks.
responsibilities associated with it. It using the DRE and PSA tests and do information regarding the benefits and this issue prior to the testing with a list some tumors may be detected by the cancer. For diagnosis of a medical evaluation. I understand that the result from any I indicated on this form, and the legal limits. They will never be release to strictly limited to those directly in	s prostate cancer screening program, I recognize and accept all risks and understand that this program will only screen for abnormalities of the prostate bes not constitute a complete medical examination or diagnosis. I have received a risks of PSA testing and exam, and have been given the opportunity to discuss icensed physician or a licensed medical professional. I understand that although a DRE and PSA test, no test is completely accurate in the detection of prostate problem, I acknowledge that I must see a physician for a complete medical lts of this screening test will be released only to me, and the health care provider, at the confidentiality of all my medical records will be maintained within current used to a third party without my written consent and access to these records will evolved with your screening and protected from unauthorized access. I have read as contents and agree to participate voluntarily.
PSA Alone	PSA & DRE

Witness Signature

Date Signed/Witnessed

Please Fill In Patient Data:			
NAME:			
DATE OF BIRTH: //			
AGE			
SOCIAL SECURITY #: XXX - XX -			

TEST NAME: PSA

Frequency	Ordering MD	Collected by:	Collect:
(X) Routine () Stat () Urgent	Massimiliano		Date & Time
() Orgent	Spaliviero, MD		

Prostate Cancer Screening Questionnaire(All information provided below will be kept confidential and protected in accordance with applicable Federal Law)

SECTION 1 (To be completed by participant)						
First NameMiddle InitialLast Name						
Date of Birth/	/ Age:					
Mailing Address:						
CityState_						
Phone # _()		digits of Social Sec	urity#			
Race (Check one) Marital Status		S (Check one)	Research (Please circle Y or N)			
White/Caucasian Black/African-American Hispanic/Latino Asian/Oriental Other/ Not specified	Married Single Divorced Widowed		May we contact you regarding participation in prostate cancer research studies? Y N			
Medical Histor	y – (Please enter or cir	rcle Y or N where a	appropriate)			
Prostate History Please circle Y or N Did you have a PSA test and/or rectal exam in the last 3 years? Y N 1. Ever have a Prostate Infection (Prostatitis)? Y N 2. Enlarged Prostate (BPH)? Y N 3. Prostate Surgery for BPH? Y N 4. *Prostate Biopsy		Family History of Cancer Circle Y(Yes), N(No) or ?(Unknown) for each below: 1. Father's father had prostate cancer? Y - N - ? 2. Father's brother(s) had prostate cancer? Y - N - ? 3. Father had prostate cancer? Y - N - ? 4. Brother had prostate cancer? Y - N - ? 5. Mother's family had prostate cancer? Y - N - ? 6. Mother's family had breast cancer? Y - N - ? 7. Mother had breast cancer? Y - N - ?				
Year Result? Negative Positive If your results were Positive for Prostate Cancer, please indicate treatment(s) below:		Medications (Check all that apply) SELECT study participants: please skip this item 1. Cardura® (doxazosin)				
Treatment Y or N 5. Brachytherapy 6. Radiation 7. Hormones 8. Radical Prostatectomy 9. Watchful Waiting			msulosin) alfuzosin) opecia (finasteride)			
Have you ever had any genetic tests for Prostate Cancer? Y N PCA3, urine test: Y N		6. Avodart® (dutasteride) 7. Jalyn (dutasteride/tamsulosin)				
4KScore, Blood Test: Y N		8. Rapaflo (silod	losin)			
Others:		None of the abo	ove			

Urinary Symptom Assessment

Over the past month. how often have you (Circle one for each question)

Over the past month. now orientave you (encie one for each question)						
Never	Less than 1 time in 5	Less than half the time	Half the time	More than half the time	Almost always	
Had the sensation of not emptying your bladder completely after you finish urinating?0	1	2	3	4	5	
Needed to urinate again in less than 2 hours?0	1	2	3	4	5	
Found that you stopped and started again several times when you urinate?0	1	2	3	4	5	
Found it difficult to postpone urination?0	1	2	3	4	5	
Had a weak urinary stream?0	1	2	3	4	5	
Had to push or strain to begin urinating?0	1	2	3	4	5	
How many times do you typically get up to urinate from						
the time you go to sleep until you rise in the morning?	0 1	2	2	3	4 5	
Total Urinary Symptom Score:						
At present, are you comfortable with your current urinary situation?Yes No						

First Name	Middle Initial	Last Name	Dat	e of Birth_	1	1
If you would like and consentyour physician, Please comp Physician Name:	lete: (Must Print C	'learly)	lood test and Dig	gital rectal	exam s	ent to
Physician Address:						_
						_
Te	_	gible physician address will no				
	SECTION 2	(To be completed by Ph	ysician)			
Digital Rectal Exam Results	:					
Normalo Declined/Refused		20–30 g (2+)		g.o (4+)		
		OR				
Digital Rectal Exam Results	: (Post Prostate C	ancer Treatment)				
Normal, expected results after	Tx (no further atte	ntion required)	0			
Abnormal, not acceptable resi	ults after Tx (furthe	rattention required).	0			
		OR				
*Abnormality	(Ca	mplete for abnormal DF	RE only)			
Asymmetry	R > L o	L > R o	Q		Base	Semina
IndurationGenera	lized o Localized	d o (indicate loca	tion(s)►	5	6	vesicle
Nodule(s)Sol	itary o Multiple	o (indicate loca	tion(s)►	3	4	$\overline{}$
Hardnessl	Firm o Moderate	e o Hard o			2	$\sqrt{_{\rm R}}$
Physician's Signature	D	ate <u>//</u>		_ \	17	/ K
Additional Physician's notes, i	f necessary:			۵	pex	
	Section	3: Follow Up (If applicable)				
Indication: Abnormal DRE ·	PSA · PSAV					
R.N. Signature:						